All In Biotech

Drug Trial Radar · NCT00603980

Staccato Alprazolam Abuse Liability

Abuse Liability Study of Staccato® Alprazolam for Inhalation in Subjects With Histories of Sedative Abuse

Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

31

Actual

Start

Jan 2008

Primary completion

Jan 2009

Study completion Jan 2009

Sponsor

Lead sponsor
Nova Pneuma Inc.Industry
Sponsor type
Industry
First posted
Jan 29, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Compare the abuse liabilities of Staccato Alprazolam, oral immediate-release alprazolam, and Staccato Placebo.

Conditions

  • Abuse Liability of Staccato Alprazolam

Interventions

  • Inhaled placebo + oral placeboDrug

    Inhaled Staccato placebo + oral placebo

  • Inhaled alprazolam 0.5 mgDrug

    Inhaled Staccato alprazolam 0.5 mg + oral placebo

  • Inhaled alprazolam 1 mgDrug

    Inhaled Staccato alprazolam 1 mg + oral placebo

  • Inhaled alprazolam 2 mgDrug

    Inhaled Staccato alprazolam 2 mg + oral placebo

  • Oral alprazolam 1 mgDrug

    Oral alprazolam 1 mg + Inhaled placebo

  • Oral alprazolam 2 mgDrug

    Oral alprazolam 2 mg + Inhaled placebo

  • Oral alprazolam 4 mDrug

    Oral alprazolam 4 mg + Inhaled placebo

  • Oral alprazolam 2 mg qualifying sessionDrug

    Qualifying session (2 mg oral alprazolam)

  • Oral placebo qualifying sessionDrug

    Qualifying control session (oral placebo)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response to EDQ Question Number 5, "Rate the Degree to Which You Would Like to Take the Drug Again"Time frame: End of day for each of the 7 crossover treatments

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.